Alterations in immune function with biologic therapies for autoimmune disease - 07/01/16

Abstract |
Autoimmune disorders, including rheumatoid arthritis, inflammatory bowel disease, psoriasis, and others, are characterized by dysregulation of various aspects of normal immunity and inflammation. Biologic agents targeting key components of the dysregulated immune response have dramatically improved patient outcomes and transformed treatment paradigms for a number of systemic inflammatory autoimmune diseases. Despite their excellent efficacy, because they do affect normal immune responsiveness, biologic agents can potentially be associated with a variety of adverse effects. Important potential adverse effects related to the use of biologic agents include immunosuppression, which might result in outcomes such as infection, and autoimmunity, that could result in paradoxical inflammation or even autoimmune disease. In this article the current clinical evidence and immunologic mechanisms of the adverse effects related to biologic agents are discussed.
Le texte complet de cet article est disponible en PDF.Key words : Biologic agents, adverse effect, infection, autoimmunity, paradoxical inflammation
Abbreviations used : ANA, AS, DMARD, IBD, ILD, NTM, RA, SLE, TNFi
Plan
| Disclosure of potential conflict of interest: A. Kavanaugh has conducted sponsored research for Amgen, AbbVie, BMS, Celgene, Eli Lilly, Genentech, Janssen, Novartis, Pfizer, Regeneron, and UCB. M. Her declares no relevant conflicts of interest. |
Vol 137 - N° 1
P. 19-27 - janvier 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
